Clinical treatment and management of invasive fungal disease in recipients of solid organ transplantation / 器官移植

With widespread application of solid organ transplantation (SOT), the incidence of postoperative invasive fungal disease (IFD) in SOT recipients has been increased year by year. In recent years, the awareness of preventive antifungal therapy for SOT recipients has been gradually strengthened. However, the problem of fungal resistance has also emerged, leading to unsatisfactory efficacy of original standardized antifungal regimens. Drug-drug interaction and hepatorenal toxicity induced by drugs are also challenges facing clinicians. In this article, the characteristics of drug-drug interaction and hepatorenal toxicity among triazole, echinocandin and polyene antifungal drugs and immunosuppressants were reviewed, and postoperative preventive strategies for IFD in different types of SOT recipients and treatment strategies for IFD caused by infection of different pathogens were summarized, aiming to provide reference for physicians in organ transplantation and related disciplines.

The diagnostic value of metagenomic next-generation sequencing in AIDS patients complicated with Pneumocystis jirovecii infection / 中华检验医学杂志

Objective:To investigate the diagnostic value of metagenomic next-generation sequencing (mNGS) in AIDS patients complicated with Pneumocystis jirovecii ( P. jirovecii) infection. Methods:This is a retrospective study. From January 2019 to June 2021, the respiratory tract and other body fluid samples of 236 cases of AIDS co-infected patients diagnosed in the AIDS Department of Changsha First Hospital were collected, along with corresponding medical histories. Traditional etiological hexamine silver staining and serum 1,3-β-D glucan (BDG) were performed simultaneously with mNGS detection, and Fisher′s exact test was used to analyze the results and compare the diagnostic performances of mNGS with those of hexamine silver staining and serum G test.Results:A total of 236 cases of AIDS patients with pulmonary infection were collected and tested. Seventy-seven cases were clinically diagnosed with Pneumocystis jiroveci pneumonia and 159 cases with non- Pneumocystis jiroveci pneumonia. Among the 236 AIDS patients with pulmonary infection, mNGS detected 77 [32.63%(77/236)] positive cases of Pneumocystis jiroveci, while hexamine silver staining detected 10[4.24%(10/236)] and serum BDG detected 146 [61.86% (146/236). Based on these clinical diagnostic results, the sensitivity of mNGS detection was 100% (77/77) for the 77 patients with Pneumocystis pneumoniae, significantly higher than that of silver hexamine staining [12.99% (10/77), P=0.046] and serum BDG [58.44% (45/77), P=0.038]. The mNGS showed good specificity, which was the same as that of hexamine silver staining [100% (159/159)] and significantly higher than that of serum BDG [36.48% (58/159), P=0.026]. With therapeutic clinical diagnosis as the reference method, the accuracy of mNGS detection was 100% (236/236). Conclusions:This study evaluated the diagnostic value of mNGS detection in AIDS patients with Pneumocystis jirovecii infection. The results showed that the sensitivity and specificity of mNGS detection were high, and it had exceptional clinical application value in the pathogenic detection of infectious diseases.

Of “Cotton Balls” and “Owl’s eyes”

@#Report of a 3-month old girl child who died due to multi-systemic infection of cytomegalovirus (CMV) involving the lungs, liver and kidneys along with pneumocystis jiroveci pneumonia (PJP). The mother of the child tested positive for CMV IgG and HIV with a very low CD4 count (160/ µl). Co-infection of cytomegalovirus and pneumocystis jiroveci always occurs in the setting of immunocompromise. Congenital CMV infection is transmitted through the placenta, especially during the first trimester and causes severe multi-systemic disease whereas perinatal infection is acquired during childbirth/ breastfeeding where the babies have maternal protective antibodies leading to much milder or asymptomatic infection. PJP is more common in infancy and presents as hypoxic pneumonia. CMV causes cyto-nucleomegaly and classic “owl’s eye” inclusions on histology while PJP presents with characteristic fluffy “cotton ball” alveolar exudates.

A multivariate prognostic score for predicting mortality of acquired immunodeficiency syndrome patients with Hypoxemic Respiratory Failure and Pneumocystis Jiroveci Pneumonia

Background Severe hypoxemic respiratory failure (SHRF) due to Pneumocystis jiroveci pneumonia (PJP) in AIDS patients represents the main cause of admission and mortality in respiratory intensive care units (RICUs) in low- and middle-income countries. Objective The objective of this study was to develop a predictive scoring system to estimate the risk of mortality in HIV/AIDS patients with PJP and SHRF. Methods We analyzed data of patients admitted to the RICU between January 2013 and January 2018 with a diagnosis of HIV infection and PJP. Multivariate logistic regression and Kaplan–Meier method were used in data analysis. The RICU and inhospital mortality were 25% and 26%, respectively. Multivariate analysis identified four independent predictors: body mass index, albumin, time to ICU admission, and days of vasopressor support. A predictive scoring system was derived and validated internally. The discrimination was 0.869 (95% confidence interval: 0.821-0.917) and calibration intercept (α) and slope (β) were 0.03 and 0.99, respectively. The sensitivity was 47.2%, specificity was 84.6%, positive predictive value was 89.2%, and negative predictive value was 82.6%. Conclusions This scoring system is a potentially useful tool to assist clinicians, in low- and medium-income countries, in estimating the RICU and inhospital mortality risk in patients with HIV/AIDS and SHRF caused by PJP.

A comparative study of methods of Pneumocystis Jiroveci pneumonia in HIV patients with CD4 count less than 200 and the clinical outcome in tertiary care hospital

Background: Pneumocystosis is an opportunistic fungal infection of the respiratory system leading to interstitial plasma cell pneumonia, caused by a taxonomically unique fungus Pneumocystis jiroveci. Major developmental stages of the organism include the small (1 to 4 μm) pleomorphic trophozoite or trophic form; the 5 to 8 μm cyst, which has a thick cell wall and contains up to eight intra cystic bodies; and the precyst, an intermediate stage. The life cycle of P. jiroveci probably involves asexual replication by the trophic form and sexual reproduction by the cyst, which ends in the release of the intra cystic bodies an intracellular stage has not been identified. Aim of study: Comparing the role of clinical diagnosis, chest radiography, sputum microscopy and polymerase chain reaction for Pneumocystis jiroveci Pneumonia in HIV seropositive patients with CD4 less than 200, to know the clinical outcome of PCP patients after treatment. 151 HIV seropositive patients were recruited for study as per inclusion criteria. Materials and methods: The study was conducted in the Department of TB and Chest Medicine, Government Stanley Medical College, Chennai from 2016-2017. Thorough clinical examination G. Allwyn Vijay, S.B. Sivaraja. A comparative study of methods of Pneumocystis Jiroveci pneumonia in HIV patients with CD4 count less than 200 and the clinical outcome in tertiary care hospital. IAIM, 2019; 6(3): 148-155. Page 149 including general and systemic examination was done meticulously with vital signs monitoring and SpO2 was measured with pulse oximetry. Results: Out of 151 HIV seropositive patients examined clinically, 81 individuals were diagnosed as PCP patients. But the sputum microscopy with Gomori methenamine silver staining which was taken as gold standard test, diagnosed 41 cases of PCP only. PCR was positive in 2 more patients who were missed in GMS staining. Sputum PCR was having the highest sensitivity (100%), highest specificity (97%), highest positive predictive value (93%) and also the highest negative predictive value (100%). Among 90 PCP patients diagnosed clinically, 74 of 90 (82.2%) patients recovered from the illness after treatment and 16 of 90 (17.8%) patients died due to illness. Conclusion: As revealed in our study, induced sputum analysis is a simple procedure, without significant adverse effects, and with a good diagnostic yield for P. jiroveci pneumonia determination in HIV-positive patients. IFAT is very sensitive and specific, though the expensive method for the detection of this organism.

Pulmonary coinfection by Pneumocystis jiroveci, Cryptococcus neoformans and cytomegalovirus in hiv patient without antiretroviral treatment

Pulmonary diseases are among the main causes of morbidity and mortality in HIV patients. Here, we present the fatal case of a 30 year-old AIDS patient, who did not undergo antiretroviral treatment, presenting pulmonary coinfection by Pneumocystis jiroveci, Cryptococcus neoformans and cytomegalovirus diagnosed in the postmortem histological examination. Concurrent pulmonary infection by these three agents is not common and, to date, apparently had not been reported in the literature.

Neumonía por Pneumocystis jiroveci post inicio de tratamiento con infliximab en paciente con enfermedad de Crohn / Pneumocystis jiroveci pneumonia following infliximab therapy in patient with Crohn's disease

There are no evidence-based guidelines about prophylaxis against Pneumocystis jiroveci pneumonia in inflammatory bowel disease. We report a case of P. jiroveci pneumonia in patient with Crohn's disease receiving infliximab and methotrexate. This case emphasizes the importance of considering the possibility of this infection in inflammatory bowel disease patients treated on biological therapy.

The Safety Profiles of Biological Drugs for Rheumatoid Arthritis / 薬剤疫学

To identify the most frequently reported preferred terms （PTs） in the cases of rheumatoid arthritis （RA） patients treated with immunosuppressive biological drugs as suspected drugs, we analyzed the cases in the Japanese Adverse Drug Event Report （JADER） database. We found that pneumonia, interstitial lung disease, Pneumocystis jiroveci pneumonia （PCP), cellulitis, sepsis, and herpes zoster were the most frequently reported PTs. We obtained the reporting odds ratio （ROR） and the time to onset of these six PTs and compared them in the cases reported for each immunosuppressant as a suspected drug. We focused on RA treatment, including five tumor necrosis factor （TNF） antagonists （infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol). For pneumonia, interstitial lung disease and sepsis, no specific correlation was observed for each immunosuppressant for RA. In the case of PCP, the highest ROR was observed in the patients treated with infliximab. The time to onset of PCP in the infliximab-treated patients （median, 0.19 yr） was significantly shorter than the onset time in the patients treated with tocilizumab, an interleukin-6 receptor blocker that is another type of drug for RA（0.32 yr, p<0.01, Mann-Whitney test). The onset time in the patients treated with golimumab （0.24 yr） was also significantly shorter than the onset time for tocilizumab（p<0.05), but the ROR was not as high. These results suggested a correlation between PCP and infliximab. In the cases of cellulitis and herpes zoster, a similar correlation was observed with tocilizumab and certolizumab pegol, respectively. We should consider these results when patients have a respiratory disorder or skin/subcutaneous tissue disorder.

<b>The Safety Profiles of Biological Drugs for Rheumatoid Arthritis </b> / 薬剤疫学

<p>To identify the most frequently reported preferred terms （PTs） in the cases of rheumatoid arthritis （RA） patients treated with immunosuppressive biological drugs as suspected drugs, we analyzed the cases in the Japanese Adverse Drug Event Report （JADER） database. We found that pneumonia, interstitial lung disease, <i>Pneumocystis jiroveci</i> pneumonia （PCP), cellulitis, sepsis, and herpes zoster were the most frequently reported PTs. We obtained the reporting odds ratio （ROR） and the time to onset of these six PTs and compared them in the cases reported for each immunosuppressant as a suspected drug. We focused on RA treatment, including five tumor necrosis factor （TNF） antagonists （infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol). For pneumonia, interstitial lung disease and sepsis, no specific correlation was observed for each immunosuppressant for RA. In the case of PCP, the highest ROR was observed in the patients treated with infliximab. The time to onset of PCP in the infliximab-treated patients （median, 0.19 yr） was significantly shorter than the onset time in the patients treated with tocilizumab, an interleukin-6 receptor blocker that is another type of drug for RA（0.32 yr, p<0.01, Mann-Whitney test). The onset time in the patients treated with golimumab （0.24 yr） was also significantly shorter than the onset time for tocilizumab（p<0.05), but the ROR was not as high. These results suggested a correlation between PCP and infliximab. In the cases of cellulitis and herpes zoster, a similar correlation was observed with tocilizumab and certolizumab pegol, respectively. We should consider these results when patients have a respiratory disorder or skin/subcutaneous tissue disorder.</p>

Neumocistosis extrapulmonar: comunicación de un caso / Extrapulmonary pneumocystosis: a case report

We report a case of a middle-age male patient, with newly HIV infection in AIDS stage diagnosis, no comorbitidies, who was hospitalized for subacute malaise, fever, self-limited unproductive cough and no bloody chronic diarrea. The diagnosis of Pneumocystis jiroveci pneumonia was performed by imagenological suspicion and stains of cysts of this pathogen with bronchoalveolar lavage samples. Treatment was initiated with oral cotrimoxazole and starting HAART with good clinical outcome. Concomitantly, an etiologic study was conducted for chronic diarrhea and through histopathological examination of colonic mucosa, numerous extracellular cystic structures Pneumocystis characteristics were observed, performing the diagnosis of extrapulmonary pneumocystosis. Extrapulmonary pneumocystosis is a rare cause of P. jiroveci infection, requires a high index of suspicion and should be approached in HIV patients with severe AIDS which is common in co-infection of various infections and is peremptory to make an etiologic diagnosis and early treatment.

Comunicamos el caso de un varón de edad mediana, con diagnóstico reciente de infección por VIH en etapa SIDA, sin otras co-morbilidades, y cuadro subagudo de compromiso del estado general, fiebre, tos poco productiva autolimitada y diarrea crónica no sanguinolenta. Se realizó el diagnóstico de neumonía por Pneumocystis jiroveci mediante sospecha imagenológica y tinción de quistes de este patógeno en muestras de lavado broncoalveolar. Se inició tratamiento con cotrimoxazol y TARV con buena evolución clínica. En forma concomitante se realizó el estudio etiológico de diarrea crónica y a través del estudio histopatológico de mucosa colónica se observaron numerosas estructuras quísticas extracelulares, características de Pneumocystis por lo que se realizó el diagnóstico de neumocistosis extrapulmonar. La neumocistosis extrapulmonar es una causa infrecuente de infección por P. jiroveci, que requiere un alto índice de sospecha en pacientes con VIH e inmunocompromiso grave, en los cuales es frecuente la co-infección de infecciones oportunistas. Es perentorio realizar un diagnóstico etiológico y tratamiento precoz.

Características clínicas, diagnósticas y pronosticas de pacientes con neumonía por Pneumocystis jiroveci en individuos infectados por virus de inmunodeficiencia humana e individuos inmunocomprometidos por otra etiología: comparative study of cases in HIV-infected patients and immunocompromised non-HIV-infected patients / Pneumocystis jiroveci pneumonia

Background: Although P. jiroveci pneumonia affects immunocompromised (IC) patients of any etiology, clinical features and prognostic outcomes are different depending if they are patients with HIV infection or other causes of IC. Objectives: To compare clinical and laboratory features as well as outcomes of P. jiroveci pneumonia in HIV versus non-HIV patients. Methods: Retrospective review of clinical records of HIV and non-HIV patients with P. jiroveci pneumonia managed at the Hospital Clínico Universidad Católica in Santiago, Chile, between 2005 and 2007. Results: We included 28 HIV and 45 non-HIV patients with confirmed P. jiroveci pneumonia. The non-HIV population was older (65 vs 36,2 years, p < 0,01), had shorter duration of symptoms (7 [1-21] vs 14 [2-45] days, p < 0,01), required more invasive techniques (60 vs 21%, p < 0,01) and RT-PCR to confirm the diagnosis (93 vs 68%, p < 0,01), were more frequently treated at intensive care units (58 vs. 25%, p < 0,01) requiring artificial ventilation (56 vs 11%, p < 0,01), and had a higher attributable mortality (33% vs 0%, p < 0,01). Conclusions: Our study confirmed that P. jiroveci pneumonia in non-HIV IC patients is more severe, more difficult to diagnose and has higher mortality that in HIV patients. Therefore, it is mandatory to optimize diagnostic and therapeutic strategies for this patients group.

Introducción: Pneumocystis jiroveci puede causar neumonía en pacientes inmunocomprometidos de cualquier etiología, pero las diferencias clínicas y pronósticas entre inmunocomprometidos por VIH y por otras causas han sido poco exploradas. Objetivo: Comparar las características clínicas, de laboratorio y pronóstico de neumonía por P. jiroveci en pacientes inmunocomprometidos por infección VIH versus no infectados por VIH. Métodos: Análisis retrospectivo de casos confirmados de neumonía por P. jiroveci en adultos con infección por VIH y no infectados, entre los años 2005 y 2007. Resultados: Se incluyeron 28 pacientes infectados por VIH y 45 no infectados, con neumonía por P. jiroveci confirmada. La población no infectada por VIH presentaba mayor edad (65 vs 36,2 años, p < 0,01), menor duración de síntomas previos a la consulta (7 [121] vs 14 [2-45] días, p < 0,01), mayor requerimiento de técnica invasora (60 vs 21%, p < 0,01) y estudio molecular (93 vs 68%, p < 0,01) para confirmación diagnóstica, mayor requerimiento de camas críticas (58 vs 25%, p < 0,01), y ventilación mecánica (56 vs 11%, p < 0,01), con mayor mortalidad atribuible (33 vs 0%, p < 0,01). Conclusiones: La neumonía por P. jiroveci en pacientes inmunocomprometidos no infectados por VIH ofrece más dificultades diagnósticas y presenta mayor gravedad y mortalidad que en pacientes con infección por VIH; por esto, es mandatario optimizar los procesos diagnóstico y terapéutico en esta población.

Falla de la profilaxis con cotrimoxazol para la neumonía por Pneumocystis jiroveci con el uso concomitante de leucovorina: Reporte de un caso / Failure of cotrimoxazole prophylaxis for Pneumocystis jiroveci pneumonia with concomitant use of leucovorin: Case report

The concomitant use of leucovorin and cotrimoxazole in PCP can lead to therapeutic failure and increased risk of death due to antagonism. It is important to keep this possible antagonistic interaction in mind even during prophylaxis. This paper presents a case with this failure outcome.

Profilaxis de neumonía por Pneumocystis jiroveci en niños y adultos sometidos a trasplante de órganos sólidos y de precursores hematopoyéticos / Prophylaxis against Pneumocystis pneumonia in pediatric and adult patients undergoing solid organ or hematopoietic stem cells transplantation

Pneumocystis jiroveci is an important pathogen in patients undergoing SOT and HSCT. Universal prophylaxis is recommended for all adults and children with SOT and HSCT, considering that its use significantly reduces the occurrence and mortality associated with pneumonia by this agent. The drug of choice is cotrimoxazole (A1) three times a week, low-dose scheme, that has proved equally effective and better tolerated than the daily regimen and/or at high doses. Prophylaxis starts 7 to 14 days post transplant in SOT recipients and post-implant in HSCT, with an average duration of 6 months except in liver and lung transplant as in HSCT with significant degree of immunosuppression, that lasts for 1 year. Alternatives for prophylaxis are dapsone (B2), aerosolized pentamidine (B2) and atovaquone (C2).

Pneumocystis jiroveci es un patógeno importante en pacientes sometidos a TOS y TPH. Se recomienda proilaxis universal a todos los pacientes adultos y niños sometidos a TOS o TPH porque su uso reduce signiicati-vamente la ocurrencia y mortalidad asociada a neumonía por este agente. El medicamento de elección es cotrimoxa-zol (A1) tres veces por semana, en dosis bajas, esquema que ha demostrado igual eicacia y mejor tolerancia que el esquema diario y/o con dosis altas. La proilaxis se inicia 7 a 14 días post trasplante en TOS y posterior al implante en TPH, con una duración promedio de 6 meses salvo en trasplante de hígado y pulmón en que se prolonga por 1 año, al igual que en TPH con grado importante de inmunosupresión. Son alternativas de profilaxis dapsona (B2), pentamidina aerosolizada (B2) y atavacuona (C2).

Evaluación de la microscopía en fresco en el diagnóstico de neumocistosis pulmonar / Microscopio examination in fresh mount preparation for the diagnosis of pulmonary pneumocystosis / Avaliagáo da microscopia a fresco no diagnóstico de pneumocistose pulmonar

Para evaluar la utilidad de la microscopia en fresco en el diagnóstico de la neumocistosis pulmonar (PCP), se aplicó una técnica de inmunofluorescencia directa (IFD) con anticuerpos monoclonales a 50 secreciones respiratorias obtenidas por lavado broncoalveolar y procesadas en forma consecutiva en el Laboratorio de Parasitología, entre el 19 de enero y el 25 de febrero de 2011. Las mismas pertenecían a pacientes con SIDA y diagnóstico presuntivo de PCP, y en todas ellas la investigación de la presencia de exudados espumosos por microscopia en fresco fue negativa. Ninguna de las muestras procesadas resultó positiva para Pneumocystis jiroveci con la IFD. En base a los resultados obtenidos se concluyó que la microscopia en fresco permanece como un método rápido, económico, sencillo y seguro para el diagnóstico de la PCP en los pacientes con SIDA internados en diferentes Salas del Hospital Muñiz. Al igual que en un estudio previo, reveló poseer una sensibilidad similar a la IFD en los pacientes evaluados.

To evaluate the usefulness of fresh microscopy for the diagnosis of pulmonary pneumocystosis (PCP), direct immunofluorescence (DIF) with monoclonal antibodies technique was applied to 50 respiratory secretions obtained by bronchoalveolar lavage and consecutively processed in the Laboratory of Parasitology from January 19, 2011 to February 25, 2011. The samples belonged to AIDS patients with presumptive diagnosis of PCP, and all of them were negative for the search of foamy exudates by wet mountmicroscopy. No positive results were obtained for Pneumocystis jiroveci with the DIF. According to the results obtained, it was concluded that fresh microscopy remains being a rapid, economic, simple and accurate method for the diagnosis of PCP in AIDS patients assisted in different Wards of the Muñiz Hospital. As in a previous study, performed in a similar cohort of patients, fresh microscopy revealed a sensitivity similar to that of DIF when applied to the diagnosis of PCP.

Para avaliar a utilidade da microscopia a fresco no diagnóstico da pneumocistose pulmonar (PCP), foi aplicada uma técnica de imunofluorescencia direta (IFD) com anticorpos monoclonais em 50 secregóes respiratórias obtidas por lavagem broncoalveolar e processadas de forma consecutiva no Laboratório de Parasitologia, entre os dias 19 de janeiro de 2011 e 25 de fevereiro de 2011. As mesmas pertenciam a pacientes com AIDS e diagnóstico presuntivo de PCP, e em todas elas a pesquisa da presenga de esfregagos espumosos por microscopia a fresco foi negativa. Nenhuma das amostras processadas resultou positiva para Pneumocystis jiroveci com a IFD. Com base nos resultados obtidos foi concluido que a microscopia a fresco permanece como um método rápido, económico, simples e seguro para o diagnóstico da PCP nos pacientes com AIDS internados em diferentes. Salas do Hospital Muñiz. Do mesmo modo que num estudo prévio, revelou possuir uma sensibilidade similar a IFD nos pacientes avaliados.

Pulmonary coinfection by Pneumocystis jiroveci and Cryptococcus neoformans

We communicate the diagnosis by microscopy of a pulmonary coinfection produced by Cryptococcus neoformans and Pneumocystis jiroveci, from a respiratory secretion obtained by bronchoalveolar lavage of an AIDS patient. Our review of literature identified this coinfection as unusual presentation. Opportunistic infections associated with HIV infection are increasingly recognized. It may occur at an early stage of HIV-infection. Whereas concurrent opportunistic infections may occur, coexisting Pneumocystis jiroveci pneumonia (PCP) and disseminated cryptococcosis with cryptococcal pneumonia is uncommon. The lungs of individuals infected with HIV are often affected by opportunistic infections and tumours and over two-thirds of patients have at least one respiratory episode during the course of their disease. Pneumonia is the leading HIV-associated infection. We present the case of a man who presented dual Pneumocystis jiroveci and cryptococcal pneumonia in a patient with HIV. Definitive diagnosis of PCP and Cryptococcus requires demonstration of these organisms in pulmonary tissues or fluid. In patients with < 200/microliter CD4-lymphocytes, a bronchoalveolar lavage should be performed. This patient was successfully treated with amphotericin B and trimethoprim sulfamethoxazole. After 1 week the patient showed clinical and radiologic improvement and was discharged 3 weeks later.

Pneumocystis jiroveci Pneumonia in a 5-month-old Boy with Agammaglobulinemia: A Case Report / 대한구급학회지

Pneumocystis jiroveci (P. jiroveci) pneumonia is known as a common opportunistic infection in patients with impaired immunity. Underlying disease or conditions related to the development of P. jiroveci pneumonia include acquired immunodeficiency syndromes, as well as malignancies and congenital immune deficiency disorders. We describe a 5-month-old boy without significant medical history who was admitted at our hospital because of fever, tachypnea, vomiting, diarrhea, and lethargy whose condition became worse within several hours after admission. A chest X-ray showed bilateral diffuse infiltration and high resolution computed tomography showed diffuse bilateral ground-glass opacity. The patient was diagnosed with P. jiroveci pneumonia by direct immunofluorescent antibody staining from lung biopsy and he was later diagnosed with agammaglobulinemia. Although the boy was treated with antibiotics, high-dose corticosteroids and mechanical ventilation, he expired on the 5th hospital day. Here, we report the case of P. jiroveci pneumonia in a boy with agammaglobulinemia.

Pulmonary coinfection by Pneumocystis jiroveci and Cryptococcus neoformans

We communicate the diagnosis by microscopy of a pulmonary coinfection produced by Cryptococcus neoformans and Pneumocystis jiroveci, from a respiratory secretion obtained by bronchoalveolar lavage of an AIDS patient. Our review of literature identified this coinfection as unusual presentation. Opportunistic infections associated with HIV infection are increasingly recognized. It may occur at an early stage of HIV-infection. Whereas concurrent opportunistic infections may occur, coexisting Pneumocystis jiroveci pneumonia (PCP) and disseminated cryptococcosis with cryptococcal pneumonia is uncommon. The lungs of individuals infected with HIV are often affected by opportunistic infections and tumours and over two-thirds of patients have at least one respiratory episode during the course of their disease. Pneumonia is the leading HIV-associated infection. We present the case of a man who presented dual Pneumocystis jiroveci and cryptococcal pneumonia in a patient with HIV. Definitive diagnosis of PCP and Cryptococcus requires demonstration of these organisms in pulmonary tissues or fluid. In patients with < 200/microliter CD4-lymphocytes, a bronchoalveolar lavage should be performed. This patient was successfully treated with amphotericin B and trimethoprim sulfamethoxazole. After 1 week the patient showed clinical and radiologic improvement and was discharged 3 weeks later.

Hypoglycemic Seizures Associated with Pentamidine for Pneumocystis jiroveci Pneumonia in a HIV Patient / 대한내과학회지

Trimethoprim-sulfamethoxazole (TMX-SMZ) is the initial treatment for Pneumocystis jiroveci pneumonia in human immunodeficiency virus (HIV) patients. About 20% of patients do not complete the TMX-SMZ treatment due to treatment failure or adverse reactions. Pentamidine isethionate has been used for P. jiroveci pneumonia as a second-line regimen. Although hypoglycemia is a common adverse effect of pentamidine, pentamidine-induced hypoglycemia has not been reported in Korea. We present an HIV patient with grand mal seizures caused by pentamidine-induced hypoglycemia who was managed successfully with IV dextrose infusion. Mental changes can occur during pentamidine treatment, but hypoglycemia is often ignored and misdiagnosed as epilepsy or stroke. It can result in seizures, coma, and even death. We should be aware of pentamidine-induced hypoglycemia, which can lead to severe neurologic deficits and diabetes mellitus.

Pneumonia por Pneumocystis jiroveci (PPC) em pacientes com SIDA atendidos em hospitais da Baixada Fluminense, Rio de Janeiro, Brasil / Pneumocystis jiroveci pneumonia in patients with HIV infection from hospitals of the Baixada Fluminense, Rio de Janeiro State, Brazil

Objetivos: Os autores investigaram a freqüência de P. jiroveci em pacientes sororreagentes para o Vírus da Imunodeficiência Humana (AIDS) atendidos em hospitais de municípios da Baixada Fluminense, bem como, reconhecer aspectos do padrão epidemiológico da infecção por P. jiroveci nesses pacientes. Método: Para a realização da pesquisa foram coletadas 266 amostras de lavado broncoalveolar de pacientes infectados pelo HIV atendidos em três hospitais da Baixada Fluminense, estado do Rio de Janeiro, Brasil. Resultados: A infecção por Pneumocystis jiroveci foi diagnosticada em 26,3% das amostras, sendo 18% no sexo masculino e 8,3% no feminino. Os gêneros apresentaram freqüências semelhantes (26,8% em homens e 25,3% em mulheres) (X2= 0,07; p>0,05) e ao considerar a infecção por faixas etárias, também não se constatou diferença significativa (H=10,7; p<0,05). Entre eles ainda foram encontrados oito casos de tuberculose representando 3% do total examinado.

Objetives: The authors investigated the P. jiroveci prevalence and the epidemiological pattern of individuals with HIV infection and pulmonary infection concomitantly. Method: Were collected 266 samples of bronchoalveolar lavae of the HIV infection patients from three hospitals from Baixada Fluminense, Rio de Janeiro State, Brazil. Results: The overall prevalence of Pneumocystis jiroveci infection was 26.3%, been 18% in male and 8.3% in female. The sexes showed similar prevalence (26.8% in men and 25.3% in women) and considering the infection stratified by age category, except to female 10-15 years old group, all of them showed infection by the P. jiroveci. Both measurements without significant differences (among sex, X2= 0,07; among age category, H=10,7, p>0,05) respectively. From this survey eight cases of tuberculosis were diagnosed, representing 3.0% of the total examined.

Pneumocystis jiroveci Pneumonia Mimicking Miliary Tuberculosis in a Kidney Transplanted Patient / 결핵및호흡기질환

Bilateral interstitial infiltration in chest radiography, which may be fine granular, reticular or of ground glass opacity, is the typical radiographic findings of Pneumocystis jiroveci pneumonia. Recently, atypical radiographic features, including cystic lung disease, spontaneous pneumothorax or nodular opacity, have been reported intermittently in patients with P. jiroveci pneumonia. We report the case of a 29-year-old woman with a transplanted kidney whose simple chest radiography and HRCT scan showed numerous miliary nodules in both lungs, mimicking miliary tuberculosis (TB). Under the presumptive diagnosis of miliary TB, empirical anti-TB medication was started. However, Grocott methenamine silver nitrate staining of a transbronchial lung biopsy tissue revealed P. jiroveci infection without evidence of TB. These findings suggest that even in TB-endemic area other etiology such as P. jiroveci as well as M. tuberculosis should be considered as an etiology of miliary lung nodules in immunocompromised patients.